Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 1/2018

Open Access 01-02-2018 | Guideline

Guidelines for treatment of renal injury during cancer chemotherapy 2016

Authors: Shigeo Horie, Mototsugu Oya, Masaomi Nangaku, Yoshinari Yasuda, Yasuhiro Komatsu, Motoko Yanagita, Yuko Kitagawa, Hiroyuki Kuwano, Hiroyuki Nishiyama, Chikashi Ishioka, Hiromasa Takaishi, Hideki Shimodaira, Akira Mogi, Yuichi Ando, Koji Matsumoto, Daisuke Kadowaki, Satoru Muto

Published in: Clinical and Experimental Nephrology | Issue 1/2018

Login to get access

Excerpt

Advances in cancer drug therapy have led to improvements in the outcomes of cancer patients, as well as increasing numbers of patients undergoing anticancer chemotherapy and molecularly targeted drug therapy. One adverse event associated with cancer drug therapy is nephrotoxicity, which impedes effective cancer therapy and diminishes the quality of life of cancer patients. Consequently, onco-nephrology has emerged as a new clinical field concerned with the management of nephrotoxicity in cancer drug therapy, creating expectations for advanced expertise and the accumulation of accurate evidence. However, while patients with renal impairment have heretofore undergone planning regarding administration of cancer drug therapy, procedures for nephropathy prevention, and measures for treatment of drug-induced nephrotoxicity in clinical settings based on tradition, experimental rules, and information from clinical trials, the soundness of the evidence for these practices has been uncertain. …
Footnotes
1
Based on Cairo-Bishop diagnostic criteria [211].
 
Literature
1.
Soveri I, Berg UB, Björk J, et al. for the SBU GFR Review Group. Measuring GFR: a systematic review. Am J Kidney Dis. 2014; 64:411-24.
2.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.PubMedCrossRef
3.
Matsuo S, Imai E, Horio M, et al. for the Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53:982-92.
4.
Levey AS, Coresh J, Greene T, et al. for the Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145:247-54.
5.
6.
Martin L, Chatelut E, Boneu A, et al. Improvement of the Cockcroft-Gault equation for predicting glomerular filtration in cancer patients. Bull Cancer. 1998;85:631–6.PubMed
7.
8.
Levey AS, Stevens LA, Schmid CH, et al. for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150:604-12.
9.
U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. Draft guidance. 2010. http://​www.​fda.​gov/​downloads/​Drugs/​GuidanceComplian​ceRegulatoryInfo​rmation/​Guidances/​UCM204959.​pdf
10.
European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Scientific_​guideline/​2014/​02/​WC500162133.​pdf
11.
Pharmaceuticals and Medical Devices Agency. On the Guideline for Clinical Evaluation of Oral Hypoglycemic Agents [in Japanese]. PFSB Notification No. 0709-1 (July 9, 2010). http://​www.​pmda.​go.​jp/​files/​000208192.​pdf
12.
Horio M, Kimura H, Takamatsu Nm et al. Dosage adjustments based on GFR: Precautions for use of eGFR [in Japanese]. Jpn J Nephrol. 2008; 50:955-8.
13.
Japanese Society of Nephrology. 2012 Chronic Kidney Disease Guide [in Japanese]. Tokyo, Japan: Tokyo Igakusha; 2012.
14.
Dooley MJ, Poole SG, Rischin D, et al. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer. 2002;38:44–51.PubMedCrossRef
15.
Poole SG, Dooley MJ, Rischin D. A comparison of bedside renal function estimates and measured glomerular filtration rate (Tc99mDTPA clearance) in cancer patients. Ann Oncol. 2002;13:949–55.PubMedCrossRef
16.
Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15:291–5.PubMedCrossRef
17.
de Lemoss ML, Hsieh T, Hamata L, et al. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies. Gynecol Oncol. 2006;103:1063–9.CrossRef
18.
Shimokata T, Ando Y, Yasuda Y, et al. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci. 2010;101:2601–5.PubMedCrossRef
19.
Ainsworth NL, Marshall A, Hatcher H, et al. Evaluation of glomerular filtration rate estimation by Cockcroft-Gault, Jelliffe, Wright and Modification of Diet in Renal Disease (MDRD) formulae in oncology patients. Ann Oncol. 2012;23:1845–53.PubMedCrossRef
20.
Hartlev LB, Boeje CR, Bluhme H, Palshof T, Rehling M. Monitoring renal function during chemotherapy. Eur J Nucl Med Mol Imaging. 2012;39:1478–82.PubMedCrossRef
21.
Craig AJ, Samol J, Heenan SD, Irwin AG, Britten A. Overestimation of carboplatin doses is avoided by radionuclide GFR measurement. Br J Cancer. 2012;107:1310–6.PubMedPubMedCentralCrossRef
22.
Dooley MJ, Poole SG, Rischin D. Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose. Ann Oncol. 2013;24:2746–52.PubMedCrossRef
23.
Shepherd ST, Gillen G, Morrison P, et al. Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. Eur J Cancer. 2014;50:944–52.PubMedCrossRef
24.
Shibata K, Yasuda Y, Kobayashi R, et al. Renal function evaluation in patients with cancer who were scheduled to receive carboplatin or S-1. Clin Exp Nephrol. 2015;19:1107–13.PubMedCrossRef
25.
Hingorani S, Pao E, Schoch G, Gooley T, Schwartz GJ. Estimating GFR in adult patients with hematopoietic cell transplant: comparison of estimating equations with an iohexol reference standard. Clin J Am Soc Nephrol. 2015;10:601–10.PubMedPubMedCentralCrossRef
26.
Goto T, Yoshimura K, Matsui Y, et al. Impact of different methods of estimating renal function on determining eligibility for cisplatin (CDDP)-based chemotherapy in patients with invasive urothelial carcinoma. Hinyokika Kiyo. 2011;57:671–6.PubMed
27.
Uozumi J, Noguchi M, Tokuda Y, et al. Is the eGFR formula adequate for evaluating renal function before chemotherapy in patients with urogenital cancer? A suggestion for clinical application of eGFR formula. Clin Exp Nephrol. 2015;19:738–45.PubMedCrossRef
28.
Inoue N, Watanabe H, Okamura K, Kondo S, Kagami S. Are the equations for the creatinine-based estimated glomerular filtration rate applicable to the evaluation of renal function in Japanese children and adult patients receiving chemotherapy? Clin Exp Nephrol. 2015;19:298–308.PubMedCrossRef
29.
Tanaka Y, Matsumoto R, Yoshimura T, et al. Clinical evaluation of calculating carboplatin doses using modification of diet in renal disease (MDRD) estimate and adverse events [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 2009;36:2593–8.PubMed
30.
Launay-Vacher V, Etessami R, Jenus N, et al. Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung. 2009;187:69–74.PubMedCrossRef
31.
Jennings S, de Lemos ML, Levin A, Murray N. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. J Oncol Pharm Pract. 2010;16:113–9.PubMedCrossRef
32.
DuBois D, et al. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863–71.CrossRef
33.
Bellomo R, Ronco C, Kellum JA, et al. for the Acute Dialysis Quality Initiative workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004; 8;R204-12.
34.
Mehta RL, Kellum JA, Shah SV, et al. for the Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11:R31.
35.
Ozono Y, et al. Drug-induced kidney injury [in Japanese]. Japanese Journal of Clinical Medicine. 2002;60 (special issue):493-500.
36.
Lahoti A, Kantarjian H, Salahudeen AK, et al. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Cancer. 2010;116:4063–8.PubMedPubMedCentralCrossRef
37.
Soares M, Salluh JI, Carvalho MS, Darmon M, Rocco JR, Spector N. Prognosis of critically ill patients with cancer and acute renal dysfunction. J Clin Oncol. 2006;24:4003–10.PubMedCrossRef
38.
Perazella MA, Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015;87:909–17.PubMedCrossRef
39.
Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7:1713–21.PubMedCrossRef
40.
41.
42.
Coca SG, Yalavarthy R, Concato J, Parikh CR. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Kidney Int. 2008;73:1008–16.PubMedCrossRef
43.
44.
45.
Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol. 2010;28:455–62.PubMedCrossRef
46.
Kern W, Braess J, Kaufmann CC, Wilde S, Schleyer E, Hiddemann W. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection. Anticancer Res. 2000;20:3679–88.PubMed
47.
48.
Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, beta2-microglobulin and total protein as markers to detect drug-induced kidney injury. Nat Biotechnol. 2010;28:463–9.PubMedCrossRef
49.
Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1:200–8.PubMedPubMedCentralCrossRef
50.
Kaseda R, iino N, Hosojima M, et al. Megalin-mediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun. 2007; 357:1130-4.
51.
Hojs R, Bevc S, Ekart R, Gorenjak M, Puklavec L. Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transplant. 2006;21:1855–62.PubMedCrossRef
52.
Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant. 2013;28:254–73.PubMedCrossRef
53.
Séronie-Vivien S, Delanaye P, Piéroni L, et al. SFBC “Biology of renal function and renal failure” working group. Cystatin C: current position and future prospects. Clin Chem Lab Med. 2008;46:1664–86.PubMed
54.
Horio M, Imai E, Yasuda Y, et al. Performance of serum cystatin C versus serum creatinine as a marker of glomerular filtration rate as measured by inulin renal clearance. Clin Exp Nephrol. 2011;15:868–76.PubMedCrossRef
55.
Benöhr P, Grenz A, Hartmann JT, Müller GA, Blaschke S. Cystatin C - a marker for assessment of the glomerular filtration rate in patients with cisplatin chemotherapy. Kidney Blood Press Res. 2006;29:32–5.PubMedCrossRef
56.
Tolkoff-Rubin NE, Rubin RH, Bonventre JV. Noninvasive renal diagnostic studies. Clin Lab Med. 1988;8:507–26.PubMed
57.
Davey PG, Gosling P. beta 2-Microglobulin instability in pathological urine. Clin Chem. 1982;28:1330–3.PubMed
58.
Westhuyzen J, Endre ZH, Reece G, Reith DM, Saltissi D, Morgan TJ. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant. 2003;18:543–51.PubMedCrossRef
59.
Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1986;18:69–73.PubMedCrossRef
60.
Ikeda H, Nagashima K, Okumura H, Takahashi A, Matsuyama S, Nagamachi Y. Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum (II). Eur J Surg Oncol. 1988;14:17–20.PubMed
61.
Bondiou MT, Bourbouze R, Bernard M, Percheron F, Perez-Gonzalez N, Cabezas JA. Inhibition of A and B N-acetyl-beta-D-glucosaminidase urinary isoenzymes by urea. Clin Chim Acta. 1985;149:67–73.PubMedCrossRef
62.
Iqbal MP, Ali AA, Waqar MA, Mehboobali N. Urinary N-acetyl-beta-D-glucosaminidase in rheumatoid arthritis. Exp Mol Med. 1998;30:165–9.PubMedCrossRef
63.
Fujita H, Narita T, Morii T, et al. Increased urinary excretion of N-acetylglucosaminidase in subjects with impaired glucose tolerance. Ren Fail. 2002;24:69–75.PubMedCrossRef
64.
Tominaga M, Fujiyama K, Hoshino T, et al. Urinary N-acetyl-beta-D-glucosaminidase in the patients with hyperthyroidism. Horm Metab Res. 1989;21:438–40.PubMedCrossRef
65.
Alge JL, Arthur JM. Biomarkers of AKI: a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol. 2015;10:147–55.PubMedCrossRef
66.
Noiri E, Doi K, Negichi K, et al. Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injury. Am J Physiol Renal Physiol. 2009; 296:F669-79.
67.
Parikh CR, Thiessen-Philbrook H, Garg AX, et al. for the TRIBE-AKI Consortium. Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol. 2013; 8:1079-88.
68.
Doi K, Negishi K, Ishizu T, et al. Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med. 2011; 39:2464-9.
69.
Ferguson MA, Vaidya VS, Waikar SS, et al. Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int. 2010;77:708–14.PubMedCrossRef
70.
Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int. 2002;62:237–44.PubMedCrossRef
71.
Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol. 2004;286:F552–63.PubMedCrossRef
72.
Huang Y, Don-Wauchope AC. The clinical utility of kidney injury molecule 1 in the prediction, diagnosis and prognosis of acute kidney injury: a systematic review. Inflamm Allergy Drug Targets. 2011;10:260–71.PubMedCrossRef
73.
Tekce BK, Uyeturk U, Tekce H, Uyeturk U, Aktas G, Akkaya A. Does the kidney injury molecule-1 predict cisplatin-induced kidney injury in early stage? Ann Clin Biochem. 2015;52:88–94.PubMedCrossRef
74.
Pennemans V, De Winter LM, Faes C, et al. Effect of pH on the stability of kidney injury molecule 1 (KIM-1) and on the accuracy of its measurement in human urine. Clin Chem Acta. 2010;411:2083–6.CrossRef
75.
Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. NGAL Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54:1012–24.PubMedCrossRef
76.
Peres LA, da Cunha AD, Jr Assumpção RA, et al. Evaluation of the cisplatin nephrotoxicity using the urinary neutrophil gelatinase-associated lipocalin (NGAL) in patients with head and neck cancer. J Bras Nefrol. 2014;36:280–8.PubMed
77.
Gaspari F, Cravedi P, Mandalà M, et al. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract. 2010;115:154–60.CrossRef
78.
Yu Y, Jin H, Holder D, et al. Urinary biomarkers trefoil factor 3 and albumin enable early detection of kidney tubular injury. Nat Biotechnol. 2010;28:470–7.PubMedCrossRef
79.
Takeda M, Komeyama T, Tsutsui T, et al. Urinary endothelin-1-like immunoreactivity in young male patients with testicular cancer treated by cis-platinum: comparison with other urinary parameters. Clin Sci (Lond). 1994;86:703–7.PubMedCrossRef
80.
Shin YJ, Kim TH, Won AJ, et al. Age-related differences in kidney injury biomarkers induced by cisplatin. Environ Toxicol Pharmacol. 2014;37:1028–39.PubMedCrossRef
81.
Merchan JR. Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency. In:UpToDate, Post TW (Ed), UpToDate, 2016.
82.
Fujita K, Masuo Y, Okumura H, et al. Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure. Pharm Res. 2016;33:269–82.PubMedCrossRef
83.
Fujita K, Sunakawa Y, Miwa K, et al. Delayed elimination of SN-38 in cancer patients with severe renal failure. Drug Metab Dispos. 2011;39:161–4.PubMedCrossRef
84.
Koshiishi H, Yasui T, Takahashi E, et al. Carboplatin and CPT-11 in a hemodialysis patient with small-cell lung cancer [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 2007;34:2071–3.PubMed
85.
Shinozaki E, Mizunuma N, Tanabe M, et al. Induction of CPT-11 in a patient on hemodialysis with metastatic rectal cancer [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 2005;32:397–9.PubMed
86.
Kennoki T, Kondo T, Kimata N, et al. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol. 2011;41:647–55.PubMedCrossRef
87.
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985;12 Suppl A:51-7.
88.
Moon HH, Seo KW, Yoon KY, et al. Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients. World J Gastroenterol. 2011;17:3510–7.PubMedPubMedCentralCrossRef
89.
Maru S, Abe T, Shinohara N, et al. Influence of baseline renal function and dose reduction of nephrotoxic chemotherapeutic agents on the outcome of metastatic urothelial carcinoma: a retrospective study. Int J Urol. 2012;19:110–6.PubMedCrossRef
90.
Iwai M, Kimura M, Yoshimura T, Yasuda T. Side effect analyses in consideration of renal functions for capecitabine-administered patients [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 2012;39:783–6.PubMed
91.
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–56.PubMedCrossRef
92.
Shimokata T, Ando Y, Yasuda Y, et al. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci. 2010;101:2601–5.PubMedCrossRef
93.
Japanese Society of Nephrology and Pharmacotherapy http://​jsnp.​org/​
94.
American Pharmacists Association. Drug Information Handbook: A Clinically Relevant Resource for All Healthcare Professionals. Lexi Comp, 2014.
95.
U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling. Draft guidance. 2010. http://​www.​fda.​gov/​downloads/​Drugs/​GuidanceComplian​ceRegulatoryInfo​rmation/​Guidances/​UCM204959.​pdf
96.
European Medicines Agency. Draft guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. http://​www.​ema.​europa.​eu/​docs/​en_​GB/​document_​library/​Scientific_​guideline/​2016/​02/​WC500200841.​pdf
97.
Fety R, Rolland F, Barberi-Heyob M, et al. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res. 1998;4:2039–45.PubMed
98.
Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:2099–105.PubMedCrossRef
99.
Ando M, Minami H, Ando Y, et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res. 2000;6:4733–8.PubMed
100.
Aronoff GM, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th, American College of Physicians, 2007.
101.
Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Oncologist. 2007;12:1070–83.PubMedCrossRef
102.
Shiroyama T, Kijima T, Komuta K, et al. Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer. Cancer Chemother Pharmacol. 2012;70:783–9.PubMedCrossRef
103.
Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21:33–64.PubMedCrossRef
104.
105.
Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73:994–1007.PubMedCrossRef
106.
Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol. 2010;30:570–81.PubMedCrossRef
107.
Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther. 1980;213:551–6.PubMed
108.
Sobrero A, Guglielmi A, Aschele C, Rosso R. Current strategies to reduce cisplatin toxicity. J Chemother. 1990;2:3–7.PubMedCrossRef
109.
de Jongh FE, van Veen RN, Veltman SJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88:1199–206.PubMedPubMedCentralCrossRef
110.
de Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol. 2001;19:3733–9.PubMedCrossRef
111.
Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep. 1999;1:156–64.PubMedCrossRef
112.
Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol. 1997;40:293–308.PubMedCrossRef
113.
Mizuno T, Ishikawa K, Sato W, et al. The risk factors of severe acute kidney injury induced by cisplatin. Oncology. 2013;85:364–9.PubMedCrossRef
114.
Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O’Leary GP Jr. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res. 1988;48:3869–74.PubMed
115.
Ikeda K, Terashima M, Kawamura H, et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol. 1998;28:168–75.PubMedCrossRef
116.
Takahashi A, et al. Differences in pharmacokinetics and nephrotoxicity according to cisplatin administration methods [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 1987;14:2944–50.PubMed
117.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer Version 2. 2014. BL-G 1 of 3. http://​www.​tri-kobe.​org/​nccn/​guideline/​urological/​english/​bladder.​pdf
118.
Erdlenbruch B, Pekrum A, Roth C, Grunewald RW, Kern W, Lakomek M. Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions. Pediatr Nephrol. 2001;16:586–93.PubMedCrossRef
119.
Finley RS, Fortner CL, Grove WR. Cisplatin nephrotoxicity: a summary of preventative interventions. Drug Intell Clin Pharm. 1985;19:362–7.PubMedCrossRef
120.
Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer. 1977;39:1357–61.PubMedCrossRef
121.
Tiseo M, Martelli O, Mancuso A, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori. 2007;93:138–44.PubMed
122.
Horinouchi H, Kubota K, Itani H, et al. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol. 2013;43:1105–9.PubMedCrossRef
123.
Hotta K, Takigawa N, Hisamoto-Sato A, et al. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol. 2013;43:1115–23.PubMedCrossRef
124.
Kishimoto T, Imamura H, Kawabata R, et al. The feasibility of CDDP administration for gastric cancer outpatients undergoing S-1/cisplatin combination therapy [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 2012;39:2304–6.PubMed
125.
Hata A, Katakami N, Masuda Y, et al. Cisplatin administration for outpatients with short hydration of less than four hours [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 2012;39:1385–8.PubMed
126.
Furukawa N, Kawaguchi R, Kobayashi H. Use of high-dose cisplatin with aprepitant in an outpatient setting. Eur J Cancer Care (Engl). 2012;21:436–41.CrossRef
127.
Giaccone G, Donadio M, Ferrati P, et al. Disorders of serum electrolytes and renal function in patients treated with cis-platinum on an outpatient basis. Eur J Cancer Clin Oncol. 1985;21:433–7.PubMedCrossRef
128.
Lavolé A, Danel S, Baudrin L, et al. Routine administration of a single dose of cisplatin ≥75 mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer. 2012;99:E43–8.PubMed
129.
Vogl SE, Zaravinos T, Kaplan BH. Toxicity of cis-diamminedichloroplatinum II given in a two-hour outpatient regimen of diuresis and hydration. Cancer. 1980;45:11–5.PubMedCrossRef
130.
Vogl SE, Zaravinos T, Kaplan BH, Wollner D. Safe and effective two-hour outpatient regimen of hydration and diuresis for the administration of cis-diamminedichloroplatinum (II). Eur J Cancer. 1981;17:345–50.PubMedCrossRef
131.
National Comprehensive Cancer Network. NCCN Chemotherapy Order Templates (NCCN Templates®)
132.
Japan Lung Cancer Society Guideline Control Committee, Japanese Society of Medical Oncology Clinical Practice Guidelines Committee. Guide to short hydration methods in cisplatin treatment [in Japanese]. May 2015. https://​www.​haigan.​gr.​jp/​uploads/​photos/​1022.​pdf
133.
Higby DJ, Wallace HJ Jr, Albert DJ, Holland JF. Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer. 1974; 33:1219-5
134.
Dumas M, de Gislain C, d’Athis P, et al. Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with cis-diamminedichloroplatinum. Cancer Chemother Pharmacol. 1989;23:37–40.PubMedCrossRef
135.
Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum (II). Cancer Treat Rep. 1979;63:1515–21.PubMed
136.
Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH. High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977;39:1372–81.PubMedCrossRef
137.
Ostrow S, Egorin MJ, Mahn D, et al. High-dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep. 1981;65:73–8.PubMed
138.
Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep. 1982;66:31–5.PubMed
139.
Santoso JT, Lucci JA 3rd, Coleman RL, Schafer I, Hannigan EV. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol. 2003;52:13–8.PubMedCrossRef
140.
Launay-Vacher V, Rey JB, Isnard-Bagnis C, et al.; for the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol. 2008; 61:903-9.
141.
Willox JC, McAllister EJ, Sangster G. Kaye SB Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer. 1986;54:19–23.PubMedPubMedCentralCrossRef
142.
Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcisło K, Szczylik C. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer. 2008;44:2608–14.PubMedCrossRef
143.
Yoshida T, Niho S, Toda M, et al. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study. Jpn J Clin Oncol. 2014;44:346–54.PubMedCrossRef
144.
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Harrap KR. Phase I studies with carboplatin at the Royal Marsden Hospital. Cancer Treat Rev. 1985; 12 Suppl A:51-7.
145.
Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res. 1984;44:1693–7.PubMed
146.
Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–56.PubMedCrossRef
147.
Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520–8.PubMedCrossRef
148.
Egorin MJ, Van Echo DA, Tipping SJ, et al. Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res. 1984;44:5432–8.PubMed
149.
Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985;45:6502–6.PubMed
150.
Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995;87:573–80.PubMedCrossRef
151.
Ando Y, Minami H, Saka H, Ando Y, Sakai S, Shimokata K. Adjustment of creatinine clearance improves accuracy of Calvert’s formula for carboplatin dosing. Br J Cancer. 1997;76:1067–71.PubMedPubMedCentralCrossRef
152.
Ando M, Minamia H, Ando Y, et al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res. 2000;6:4733–8.PubMed
153.
Shimokata T, Ando Y, Yasuda Y, et al. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci. 2010;101:2601–5.PubMedCrossRef
154.
Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694–703.PubMedCrossRef
155.
Von Hoff DD, Penta JS, Helman LJ, Slavik M. Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep. 1977;61:745–8.
156.
Mir O, Ropert S, Babinet A, et al. Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma. Cancer Chemother Pharmacol. 2010;66:1059–63.PubMedCrossRef
157.
Romolo JL, Goldberg NH, Hande KR, Rosenberg SA. Effect of hydration on plasma-methotrexate levels. Cancer Treat Rep. 1977;61:1393–6.PubMed
158.
Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med. 1977;297:630–4.PubMedCrossRef
159.
Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004;100:2222–32.PubMedCrossRef
160.
Flombaum CD, Meyers PA. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999;17:1589–94.PubMedCrossRef
161.
Buchen S, Ngampolo D, Melton RG, et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005;92:480–7.PubMedPubMedCentralCrossRef
162.
Widemann BC, Balis FM, Kim A, et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol. 2010;28:3979–86.PubMedPubMedCentralCrossRef
163.
Wall SM, Johansen MJ, Molony DA, DuBose TD Jr, Jaffe N, Madden T. Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis. 1996;28:846–54.PubMedCrossRef
164.
Saland JM, Leavey PJ, Bash RO, Hansch E, Arbus GS, Quigley R. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol. 2002;17:825–9.PubMedCrossRef
165.
Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signaling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010;46:439–48.PubMedCrossRef
166.
Kandula P, Agarwal R. Proteinuria and hypertension with tyrosine kinase inhibitors. Kidney Int. 2011;80:1271–7.PubMedCrossRef
167.
Avastin® for intravenous infusion: special drug use surveillance final analysis results [in Japanese]. All-case surveillance for unresectable metastatic colorectal cancer.
168.
Sutent® capsules 12.5 mg special drug use surveillance final report [in Japanese]. Created Mar 2012.
169.
Nexavar® tablets 200 mg (generic name: sorafenib tosylate tablets) special drug use surveillance final report [in Japanese]. Oct 2012. http://​www.​nexavar.​jp/​unmember/​pdf/​rcc201305.​pdf
170.
Tomita Y, Uemura H, Fujimoto H, et al.; for the Japan Axitinib Phase II Study Group. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer. 2011; 47:2592-602.
171.
Wu S, Keresztes RS. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. Cancer Invest. 2011;29:460–71.PubMed
172.
173.
Land JD, Chen AH, Atkinson BJ, Cauley DH, Tannir NM. Proteinuria with first—line therapy of metastatic renal cell cancer. J Oncol Pharm Pract. 2016;22:235–41.PubMedCrossRef
174.
Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL, Whorf R. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28:2131–6.PubMedCrossRef
175.
Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol. 2010;21:184–5.PubMedCrossRef
176.
177.
Costero O, Picazo ML, Zamora P, Romero S, Martinez-Ara J, Selgas R. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy. Nephrol Dial Transplant. 2010;25:1001–3.PubMedCrossRef
178.
Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164–72.PubMed
179.
Hillner BE, Ingle JN, Chlebowski RTet al. for the American Society of Clinical Oncology. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003; 21:4042-57.
180.
Kyle RA, Yee GC, Somerfield MR, et al. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25:2464–72.PubMedCrossRef
181.
Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377–87.PubMed
182.
Rosen LS, Gordon DH, Dugan W Jr, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36–43.PubMedCrossRef
183.
Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735–44.PubMedCrossRef
184.
Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150–7.PubMedCrossRef
185.
Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors:a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613–21.PubMedCrossRef
186.
Shah SR, Jean GW, Keisner SV, Ussery SM, Dowell JE. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid. Support Care Cancer. 2012;20:87–93.PubMedCrossRef
187.
Pivot X, Lortholary A, Abadie-Lacourtoisie S, et al. Renal safety of ibandronate 6 mg infused over 15 min versus 60 min in breast cancer patients with bone metastases: a randomized open-label equivalence trial. Breast. 2011;20:510–4.PubMedCrossRef
188.
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125–32.PubMedCrossRef
189.
Miyakawa M, Sugimoto K, Ohe Y, Masuoka H, Miyahara T. Pharmacokinetics of cis-dichlorodiammine platinum (II) in patients undergoing hemodialysis [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 1987;14:2491–5.PubMed
190.
Miyakawa M, et al. Cisplatinum-centered chemotherapy for gastric cancer in maintenance dialysis patients [in Japanese]. Kidney and Dialysis. 1987;23:179–82.
191.
Inozume T, Nakamura Y, Aoki R, et al. DAC-Tam therapy as a treatment of the progressive stage of melanoma in a patient on maintenance hemodialysis [in Japanese]. Skin Cancer. 2005;20:93–8.CrossRef
192.
Suwata J, Hiraga S, Hida M, Takamiya T, Iida T, Sato T. Study on changes in plasma platinum concentrations after administration of CDDP to maintenance hemodialysis patients [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 1988;15:243–8.PubMed
193.
Gouyette A, Lemoine R, Adhemar JP, et al. Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. Cancer Treat Rep. 1981;65:665–8.PubMed
194.
Yokogi H, et al. Combination therapy with methotrexate, vinblastine, adriamycin, and cis-platinum for ureteral cancer with comorbid chronic renal failure [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 1993;20:2405–7.PubMed
195.
Shimizu M, et al. Daily concurrent chemoradiotherapy using super-selective intra-arterial infusion via the superficial temporal artery and the occipital artery for an advanced tongue cancer patient with chronic renal failure: analysis of platinum pharmacokinetics in blood [in Japanese]. J Jpn Soc Oral Tumor. 2010;22:45–51.CrossRef
196.
Arai Y, Oyama T, Hotta K, Tomori A, Miyata Y. Successful treatment with 5-Fluorouracil and cis-dichlorodiammineplatinum combined with 60Gy of radiation in a case of advanced esophageal cancer complicated with chronic renal failure treated with hemodialysis [in Japanese]. Journal of Japanese Society of Gastroenterology. 2008;105:1482–8.PubMed
197.
Suzuki T, Shiga K, Kobayashi T. Selective intraarterial infusion chemotherapy in a patient with maxillary carcinoma under artificial hemodialysis [in Japanese]. Practica Otologica. 2006;99:439–44.CrossRef
198.
Tokunaga Jkikukawa H, Nishi K, et al. Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 2000;27:2079–85.
199.
Satoh T, Nishida M, Sano A, Kotake Y, Tsunoda H, Kubo T. Consecutive serum concentrations of cisplatinum in a patient with endometrial carcinoma during hemodialysis [in Japanese]. Acta Obstetrica et Gynaecologica Japonica. 1996;48:303–6.PubMed
200.
Ayabe H, Uchikawa T, Kimino K, Tagawa Y, Kawahara K, Tomita M. Pharmacokinetics of cisplatin and vindesine in a patient with chronic renal failure undergoing hemodialysis [in Japanese]. Japanese Journal of Cancer and Chemotherapy. 1989;16:3283–5.PubMed
201.
Goto N, et al. Pharmacokinetics of cisplatin and fluorouracil in hemodialysis patients [in Japanese]. The Japanese Journal of Therapeutic Drug Monitoring. 1988;15:329–33.
202.
Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol. 2010;21:1395–403.PubMedCrossRef
203.
Lichtman SM, Wildiers H, Launay-Vacher V, Steer C, Chatelut E, Aapro M. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer. 2007;43:14–34.PubMedCrossRef
204.
Japanese Society of Medical Oncology. Tumor Lysis Syndrome Practice Guidance [in Japanese]. Kanehara Shuppan, 2013.
205.
Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone–results of a multicenter phase III study. J Clin Oncol. 2010;28:4207–13.PubMedPubMedCentralCrossRef
206.
Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998–3003.PubMedCrossRef
207.
Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database Syst Rev. 2014; 8:CD006945.
208.
Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005;19:34–8.PubMedCrossRef
209.
Vadhan-Raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012;23:1640–5.PubMedCrossRef
210.
Kikuchi A, Kigasawa H, Tsurusawa M, et al. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome. Int J Hematol. 2009;90:492–500.PubMedCrossRef
211.
Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11.PubMedCrossRef
212.
Kagami S, Okada H, Kaname S, et al. Diagnostic criteria of atypical hemolytic uremic syndrome [in Japanese]. Jpn J Nephrol. 2013;55:91–3.
213.
Matsui K, Yasuda T. Drug/transplant-induced atypical hemolytic uremic syndrome [in Japanese]. Jpn J Nephrol. 2014;56:1067–74.
214.
Chow S, Roscoe J, Cattran DC. Plasmapheresis and antiplatelet agents in the treatment of the hemolytic uremic syndrome secondary to mitomycin. Am J Kidney Dis. 1986;7:407–12.PubMedCrossRef
215.
Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989;7:781–9.PubMedCrossRef
216.
Cantrell JE Jr, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol. 1985;3:723–34.PubMedCrossRef
217.
Fisher DC, Sherrill GB, Hussein A, et al. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transplant. 1996;18:193–8.PubMed
218.
Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer. 2004;100:2664–70.PubMedCrossRef
Metadata
Title
Guidelines for treatment of renal injury during cancer chemotherapy 2016
Authors
Shigeo Horie
Mototsugu Oya
Masaomi Nangaku
Yoshinari Yasuda
Yasuhiro Komatsu
Motoko Yanagita
Yuko Kitagawa
Hiroyuki Kuwano
Hiroyuki Nishiyama
Chikashi Ishioka
Hiromasa Takaishi
Hideki Shimodaira
Akira Mogi
Yuichi Ando
Koji Matsumoto
Daisuke Kadowaki
Satoru Muto
Publication date
01-02-2018
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1448-z

Other articles of this Issue 1/2018

Clinical and Experimental Nephrology 1/2018 Go to the issue

Review article

Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology

Original article

Urinary biomarkers in the early detection and follow-up of tubular injury in childhood urolithiasis

Original article

Premature mortality due to nephrotic syndrome and the trend in nephrotic syndrome mortality in Japan, 1995–2014

Original article

Comparison of different definitions of acute kidney injury in extremely low birth weight infants

Images in nephrology

Pulmonary nonsegmental micronodules in a patient undergoing hemodialysis

Original article

Home-based versus center-based aerobic exercise on cardiopulmonary performance, physical function, quality of life and quality of sleep of overweight patients with chronic kidney disease
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits